Fonseca Biosciences Drug Patent Portfolio
Fonseca Biosciences owns 1 orange book drug protected by 6 US patents Given below is the list of Fonseca Biosciences's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US9504691 | Finafloxacin suspension compositions | 21 Nov, 2033 | Active |
US8536167 | Methods for treating ophthalmic, otic, or nasal infections | 08 Aug, 2031 | Active |
US9119859 | Methods for treating otic infections | 02 Jul, 2030 | Active |
US9993483 | Compositions and methods for treating ophthalmic, octic, or nasal infections | 02 Jul, 2030 | Active |
US6133260 | Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of Helicobacter pylori infections and associated gastroduodenal diseases | 12 Apr, 2017 | Expired |
US6432948 | Use of 7-(2-oxa-5,8-diazabicylco[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of heliobacter pylori infections and associated gastroduodenal diseases | 12 Apr, 2017 | Expired |
Latest Legal Activities on Fonseca Biosciences's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Fonseca Biosciences.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 8th Yr, Small Entity | 06 May, 2024 | US9504691 |
Payment of Maintenance Fee, 8th Yr, Small Entity | 21 Feb, 2023 | US9119859 |
Change in Power of Attorney (May Include Associate POA)
Critical
| 23 Nov, 2022 | US9993483 |
Change in Power of Attorney (May Include Associate POA)
Critical
| 14 Nov, 2022 | US9119859 |
Change in Power of Attorney (May Include Associate POA)
Critical
| 10 Nov, 2022 | US9504691 |
Change in Power of Attorney (May Include Associate POA)
Critical
| 10 Nov, 2022 | US8536167 |
Change in Power of Attorney (May Include Associate POA)
Critical
| 26 Oct, 2022 | US9119859 |
Change in Power of Attorney (May Include Associate POA)
Critical
| 26 Oct, 2022 | US9993483 |
Change in Power of Attorney (May Include Associate POA)
Critical
| 26 Oct, 2022 | US8536167 |
Change in Power of Attorney (May Include Associate POA)
Critical
| 26 Oct, 2022 | US9504691 |
Payment of Maintenance Fee, 4th Yr, Small Entity | 13 Dec, 2021 | US9993483 |
Payment of Maintenance Fee, 8th Yr, Small Entity | 30 Sep, 2020 | US8536167 |
Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 06 Jul, 2020 | US9119859 |
Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 06 Jul, 2020 | US9993483 |
Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 06 Jul, 2020 | US8536167 |
Fonseca Biosciences's Family Patents
Fonseca Biosciences Drug List
Given below is the complete list of Fonseca Biosciences's drugs and the patents protecting them.
1. Xtoro
Xtoro is protected by 6 patents, out of which 2 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US9504691 | Finafloxacin suspension compositions |
21 Nov, 2033
(8 years from now)
| Active |
US8536167 | Methods for treating ophthalmic, otic, or nasal infections |
08 Aug, 2031
(6 years from now)
| Active |
US9119859 | Methods for treating otic infections |
02 Jul, 2030
(5 years from now)
| Active |
US9993483 | Compositions and methods for treating ophthalmic, octic, or nasal infections |
02 Jul, 2030
(5 years from now)
| Active |
US6133260 | Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of Helicobacter pylori infections and associated gastroduodenal diseases |
12 Apr, 2017
(7 years ago)
| Expired |
US6432948 | Use of 7-(2-oxa-5,8-diazabicylco[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of heliobacter pylori infections and associated gastroduodenal diseases |
12 Apr, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xtoro's drug page